| Author | Calvet, Claudia Magalhães | |
| Author | Silva, Tatiana Araújo | |
| Author | Thomas, Diane | |
| Author | Suzuki, Brian | |
| Author | Hirata, Ken | |
| Author | Siqueira Neto, Jair Lage | |
| Author | McKerrow, James H. | |
| Access date | 2021-02-21T13:08:54Z | |
| Available date | 2021-02-21T13:08:54Z | |
| Document date | 2020 | |
| Citation | CALVET, Claudia Magalhães et al. Long term follow-up of Trypanosoma cruzi infection and Chagas disease manifestations in mice treated with benznidazole or posaconazole. PLOS Neglected Tropical Diseases, v. 14, n. 9, p. 1-14, Sept. 2020. | pt_BR |
| ISSN | 1935-2727 | pt_BR |
| URI | https://www.arca.fiocruz.br/handle/icict/46119 | |
| Language | eng | pt_BR |
| Publisher | Public Library of Science | pt_BR |
| Rights | open access | |
| Subject in Portuguese | Trypanosoma cruzi | pt_BR |
| Subject in Portuguese | Doença de Chagas | pt_BR |
| Subject in Portuguese | Posaconazole | pt_BR |
| Subject in Portuguese | Benznidazole | pt_BR |
| Title | Long term follow-up of Trypanosoma cruzi infection and Chagas disease manifestations in mice treated with benznidazole or posaconazole | pt_BR |
| Type | Article | |
| DOI | 10.1371/journal.pntd.0008726 | |
| Abstract | Chagas’ Disease, caused by the protozoan parasite Trypanosoma cruzi, is responsible for
up to 41% of the heart failures in endemic areas in South America and is an emerging infection
in regions of North America, Europe, and Asia. Treatment is suboptimal due to two factors.
First, the lack of an adequate biomarker to predict disease severity and response to
therapy; and second, up to 120-days treatment course coupled with a significant incidence
of adverse effects from the drug currently used. Because the disease can manifest itself clinically
a few years to decades after infection, controversy remains concerning the suitability
of current drug treatment (benznidazole), and the efficacy of alternative drugs (e.g. posaconazole).
We therefore followed the clinical course, and PCR detection of parasite burden, in
a mouse model of infection for a full year following treatment with benznidazole or posaconazole.
Efficacy of the two drugs depended on whether the treatment was performed during
the acute model or the chronic model of infection. Posaconazole was clearly superior in
treatment of acute disease whereas only benznidazole had efficacy in the chronic model.
These results have important implications for the design and analysis of human clinical trials,
and the use of specific drugs in specific clinical settings. | pt_BR |
| Affilliation | Center for Discovery and Innovation in Parasitic Diseases, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California. San Diego, California, USA / Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Ultraestrutura Celular. Rio de Janeiro, RJ, Brasil. | pt_BR |
| Affilliation | Center for Discovery and Innovation in Parasitic Diseases, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California. San Diego, California, USA / Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Ultraestrutura Celular. Rio de Janeiro, RJ, Brasil. | pt_BR |
| Affilliation | Center for Discovery and Innovation in Parasitic Diseases, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California. San Diego, California, USA. | pt_BR |
| Affilliation | Center for Discovery and Innovation in Parasitic Diseases, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California. San Diego, California, USA. | pt_BR |
| Affilliation | Center for Discovery and Innovation in Parasitic Diseases, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California. San Diego, California, USA. | pt_BR |
| Affilliation | Center for Discovery and Innovation in Parasitic Diseases, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California. San Diego, California, USA. | pt_BR |
| Affilliation | Center for Discovery and Innovation in Parasitic Diseases, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California. San Diego, California, USA. | pt_BR |
| Subject | Trypanosoma cruzi | pt_BR |
| Subject | Chagas disease | pt_BR |
| Subject | Benznidazole | pt_BR |
| Subject | Posaconazole | pt_BR |
| xmlui.metadata.dc.subject.ods | 03 Saúde e Bem-Estar | |
